CA Tumor Markers Testing Market - Forecast(2024 - 2030)

CA Tumor Markers Testing Market size is estimated to reach $261.7 million by 2028, growing at a CAGR of 6.7% during the forecast period 2023-2028. CA Tumor Markers like CA-125 tumor marker blood tests involve a test that assesses the quantity of a protein termed CA-125 (cancer antigen 125) in a sample of the blood. The tumor markers list includes CA15-3/CA27.29 associated with breast cancer and more. Considering an examination of tumor markers in 2022, cancer antigen 125 (CA-125) tests are the basic ovarian cancer tumor marker tests. Certain tumor markers for breast cancer include CA 15-3 and CA 27.29. The soaring technological breakthroughs for discovering targeted tumors with tumor marker blood tests are set to drive the CA Tumor Markers Testing Market. The expanded focus on maintaining a better quality of life is set to propel the growth of the CA Tumor Markers Testing Industry during the forecast period 2023-2028. This represents the CA Tumor Markers Testing Industry Outlook.

CA Tumor Markers Testing Market Report Coverage

The “CA Tumor Markers Testing Market Report - Forecast (2023-2028)” by IndustryARC, covers an in-depth analysis of the following segments in the CA Tumor Markers Testing Market.

Key Takeaways

• Geographically, North America (CA Tumor Markers Testing market share) accounted for the highest revenue share in 2021 and it is poised to dominate the market over the period 2023-2028 due to the massive base of cancer patients requiring tumor marker blood tests in the North American region.
• The growth of the CA Tumor Markers Testing Market is being driven by the rising rate of incidence of cancer. However, cancer biomarkers in the tumor markers list can vacillate over time, not yielding constant outcomes with repeated testing. This is one of the major factors hampering the growth of the CA Tumor Markers Testing Market.
• The CA Tumor Markers Testing Market's detailed analysis of the Strengths, Weaknesses and Opportunities of the prominent players operating in the market would be provided in the CA Tumor Markers Testing Market report.

CA Tumor Markers Testing Market Segment Analysis - by Technology

The CA Tumor Markers Testing Market based on technology can be further segmented into Radioimmunoassay (RIA), Enzyme Immunoassays (EIA), PCR, Latex Agglutination, Immuno-PCR and Nucleic Acid Sequence Based Amplification (NASBA). The Radioimmunoassay (RIA) segment held the largest share of the CA Tumor Markers Testing market in 2021. This growth is fueled by the increasing application of radioimmunoassay-based CA tumor marker tests like CA 19-9. The increasing application of radioimmunoassay in an extensive assortment of medical applications is further propelling the growth of the Radioimmunoassay (RIA) segment. Furthermore, the Enzyme Immunoassays (EIA) segment is estimated to grow with the fastest CAGR of 7.3% during the forecast period 2023-2028 due to the emerging application of enzyme immunoassay (EIA) as a blood or urine analysis that can assist in the diagnosis of numerous infections and inflammatory conditions.

CA Tumor Markers Testing Market Segment Analysis - by Type

The CA Tumor Markers Testing Market based on type can be further segmented into Cancer Antigen 125 (CA 125), Cancer Antigen 27-29 (CA 27-29), Cancer Antigen 19-9 (CA 19-9) and Cancer Antigen 15-3 (CA 15-3). The Cancer Antigen 15-3 (CA 15-3) Segment held the largest share of the CA Tumor Markers Testing market in 2021. This growth is driven by the increasing application of the Cancer Antigen 15-3 (CA 15-3) test associated with treatment for invasive breast cancer. The increasing application examining the recurrence of breast cancer is further propelling the growth of this segment. Furthermore, the Cancer Antigen 27-29 (CA 27-29) segment is estimated to grow with the fastest CAGR of 7.5% during the forecast period 2023-2028 due to the increasing clinical application of CA 27-29 in the detection of recurrent breast cancer.

CA Tumor Markers Testing Market Segment Analysis - by Geography

The CA Tumor Markers Testing Market based on geography can be further segmented into North America, Europe, Asia-Pacific, South America and the Rest of the World. North America (CA Tumor Markers Testing Market) dominated the CA Tumor Markers Testing market with a 41% share of the overall market in 2021. The growth of this region is fueled by the increasing count of new cases of cancer in the North American region. The rising application of tumor markers in 2022 is further propelling the growth of the CA Tumor Markers Testing Market in the North American region.

Furthermore, the Asia-Pacific region is estimated to be the fastest-growing region in the market over the forecast period 2023-2028. This growth is driven by factors like the soaring rate of acceptance of progressive cancer screening tools in the Asia-Pacific region. The high potential is further fueling the progress of the CA Tumor Markers Testing Market in the Asia-Pacific region.

CA Tumor Markers Testing Market Drivers

Increasing Tumor Markers for Breast Cancer:

As per World Health Organization (WHO), breast cancer five-year survival rates in high-income countries surpass 90%, in comparison with 66% in India and 40% in South Africa. Tumor marker blood tests are blood tests utilized to detect some cancer markers, which may assist in diagnosing breast cancer. Tumor markers for breast cancer may be utilized for screening for cancer, monitoring progression, recognizing recurrence and monitoring treatment response. Tumor marker blood tests like CA 15-3 and CA 27.29 are the ones most typically utilized. The increasing usage of tumor markers for breast cancer is therefore fueling the growth of the CA Tumor Markers Testing Market during the forecast period 2023-2028.

Promising Advantages of Utilization of Tumor Markers:

The tumor markers list may include tumor markers like CA19-9 associated principally with pancreatic cancer, but also with colorectal cancer and additional kinds of gastrointestinal cancer. As per a study considering tumor markers in 2022, cancer antigen 125 (CA-125) tests are the principal ovarian cancer tumor marker tests. CA-125 is also part of the tumor markers list. Application of tumor markers offers benefits like supplying greater information regarding the ailment to permit the utilization of customized treatments leading to enhanced efficiency and survival. As per Healthline, the normal test result of CA 15.3 is less than 30 U/mL. The promising advantages of utilization of tumor markers are therefore driving the growth of the CA Tumor Markers Testing Market during the forecast period 2023-2028.

CA Tumor Markers Testing Market Challenges

Limitations of Tumor Markers:

As per Healthline, the high test result value of CA 125 is greater than 35 U/mL. Not all cancer types have a suitable tumor marker test. At times, patients without cancer may have raised tumor marker levels. Certain non-cancerous health conditions also bring about high levels. In certain people, tumor marker levels do not climb until the cancer has worsened. This can make it more difficult to diagnose cancer or repeat cancer in its early phases. These issues are thus hampering the growth of the CA Tumor Markers Testing Market.

CA Tumor Markers Testing Industry Outlook

Technological breakthroughs in tumor diagnosis and therapy and R&D activities are key strategies adopted by players in the CA Tumor Markers Testing Market. The top 10 companies in the CA Tumor Markers Testing market are:

1. Abbott Laboratories
2. Becton, Dickinson and Company
3. Applied Genetic Technologies Corporation
4. bioMérieux SA
5. Cepheid
6. Correlogic Systems, Inc.,
7. Myriad Genetics
8. Panacea Pharmaceuticals
9. Qiagen
10. Radiant Pharmaceuticals

Recent Developments

• In February 2022, Becton, Dickinson and Company declared the acquisition of Cytognos. The terms of the acquisition were not revealed. The transaction provides Becton exclusive access to assays licensed from EuroFlow Consortium.
• In July 2021, Becton, Dickinson and Company declared that it acquired Tepha, Inc. Tepha Inc., is a chief developer and manufacturer of proprietary resorbable polymer technology. This acquisition fuels innovations in soft tissue repair and regeneration.
• In December 2020, LGC Maine Standards declared the discharge of VALIDATE® Tumor Markers. This was performed to fit the linearity and calibration verification requirements of clinical laboratories. These laboratories operate the Abbott Architect and Abbott Affinity platforms. 

Relevant Reports:

Ovarian Cancer Drugs Market - Industry Analysis, Market Size, Share, Trends, Application Analysis, Growth and Forecast Analysis

Report Code: HCR 0350

Liquid Biopsy Market - Industry Analysis, Market Size, Share, Trends, Application Analysis, Growth and Forecast Analysis

Report Code: HCR 0292

Genetic Testing Market - Industry Analysis, Market Size, Share, Trends, Application Analysis, Growth and Forecast Analysis

Report Code: HCR 0084

For more Lifesciences and Healthcare Market reports, please click here